Form 4: Edgewise Therapeutics General Counsel John R. Moore Reports Stock Option and RSU Grants
SEC Form 4 Filing
John R. Moore, General Counsel of Edgewise Therapeutics, reports the acquisition of stock options and restricted stock units (RSUs) on August 12, 2024.
Summary
- On August 12, 2024, John R. Moore, the General Counsel of Edgewise Therapeutics, Inc., was granted stock options to purchase 138,750 shares of common stock at an exercise price of $17.05.
- These options vest monthly over four years, starting August 12, 2024, contingent upon continued service.
- Moore also received 23,125 Restricted Stock Units (RSUs), each representing a right to receive one share of Edgewise Therapeutics common stock.
- The RSUs vest in four equal annual installments beginning on August 12, 2024.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of interests. It's a neutral-positive event.
Positives
- The grant of stock options and RSUs to the General Counsel aligns his interests with those of the shareholders.
- The vesting schedules incentivize continued service and commitment to the company's long-term success.
Future Outlook
The document does not contain any specific forward-looking statements regarding the company's future performance.
Industry Context
Granting stock options and RSUs to key executives is a common practice in the biotechnology industry to incentivize performance and retain talent. This aligns with standard compensation practices in similar companies.
Comparison to Industry Standards
- Companies like Sarepta Therapeutics and BioMarin Pharmaceutical also utilize stock options and RSUs as part of their executive compensation packages.
- The vesting schedules and grant sizes are generally comparable to industry norms for similar roles and company sizes.
Stakeholder Impact
- Shareholders may view the grants positively as they incentivize management to increase shareholder value.
- Employees may see this as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 08/12/2024 | Date of transaction: grant of stock options and RSUs. |
| 08/12/2024 | Vesting start date for both stock options and RSUs. |
| 08/12/2034 | Expiration date for the stock options. |
| 08/14/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.